Trovafloxacin Mesylate

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Achtung

• Gefahrenhinweise

  H314：Verursacht schwere Verätzungen der Haut und schwere Augenschäden.

  H361：Kann vermutlich die Fruchtbarkeit beeinträchtigen oder das Kind im Mutterleib schädigen.

• Sicherheit

  P201：Vor Gebrauch besondere Anweisungen einholen.

  P260：Dampf/Aerosol/Nebel nicht einatmen.

  P280：Schutzhandschuhe/Schutzkleidung/Augenschutz tragen.

  P301+P330+P331：BEI VERSCHLUCKEN: Mund ausspülen. KEIN Erbrechen herbeiführen.

  P303+P361+P353：BEI BERÜHRUNG MIT DER HAUT (oder dem Haar): Alle kontaminierten Kleidungsstücke sofort ausziehen. Haut mit Wasser abwaschen oder duschen.

  P305+P351+P338：BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen.

Trovafloxacin Mesylate Chemische Eigenschaften,Einsatz,Produktion Methoden

• Beschreibung

  Trovafloxacin is a broad spectrum antibiotic that inhibits the uncoiling of supercoiled DNA in bacteria by blocking the activity of topoisomerase IV (IC₅₀ = 3.02 μg/ml) and DNA gyrase (IC₅₀ = 7.13 μg/ml).

• Chemische Eigenschaften

  White Solid

• Originator

  Trovan,Pfizer,USA

• Verwenden

  Trovafloxacin mesylate has been used as a test compound in toxicity assay to assess its toxicity in 2D hepatocyte cultures. It has also been used to manipulate the mechanism of apoptotic cell disassembly during apoptosis.

• Verwenden

  Fluorinated quinolone antibacterial. Trovafloxacin mesylate blocks the activity of DNA gyrase and topoisomerase IV, enzymes essential in the repliction, transcription, and repair of bacterial DNA.

• Definition

  ChEBI: A methanesulfonate (mesylate) salt prepared from equimolar amounts of trovafloxacin and methanesulfonic acid. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.

• Manufacturing Process

  N-Benzylmaleimide (500 g, 2.67 mole), 90% bromonitromethane (831 g, 5.34 mole), powdered molecular sieves 200 mesh (2020 g) and toluene (12 dm3) were stirred under nitrogen at -10°C. 1,2-Dimethyl-1,4,5,6- tetrahydropyrimidine (616 g, 5.49 mole) was added slowly over about 3 h maintaining the reaction temperature at <-8°C throughout the addition. After completion of the addition, the reaction mixture was stirred for 1.5 h at 25°C, filtered under a nitrogen atmosphere in a sealed pressure filter to remove sieves and resulting tar, and the sieves were washed with toluene (2 L). The combined filtrates were washed with 2 N dilute hydrochloric acid (3 times 750 cm3), treated with carbon (50 g) at 70°C, 1 h filtered, concentrated, and triturated with 2-propanol (about 4 dm3) to obtain crystals of the (1α,5α,6α)- 3-N-benzyl-6-nitro-2,4-dioxo-3-azabicyclo[3.1.0]hexane (223 g, 34%) melting point 116°-118°C.
  Tetrahydrofuran (350 cm3), sodium borohydride (14.1 g) and (1α,5α,6α)-3-N_x0002_benzyl-6-nitro-2,4-dioxo-3-azabicyclo[3.1.0]hexane (35.0 g, mmol) obtained above were stirred under nitrogen for 0.25 h and then treated dropwise with boron trifluoride-THF complex containing 21.5% BF3 (44.9 cm3) so that the exotherm was controlled to <40°C. After addition was completed, the reaction mixture was stirred for 3 h at 40°C, quenched slowly with water/THF 1:1 (70 cm3) to avoid excessive foaming, and stirred for 0.5 h at 50°C to ensure that the quench of unreacted diborane generated in situ was completed. The quench formed a salt slurry which was filtered and washed with THF (140 cm3); the combined filtrate was partially concentrated, diluted with water (350 cm3) and further concentrated to remove most of the THF, and extracted with ethyl acetate (140 cm3). The resulting ethyl acetate solution was concentrated to afford the (1α,5α,6α)-3-N-benzyl-6-nitro-3-azabicyclo[3.1.0]hexane as a clear oil (30.6 g, 97%).
  (1α,5α,6α)-3-N-Benzyl-6-nitro-3-azabicyclo[3.1.0]hexane (30.9 g, 142 mmol) obtained above, 2-propanol (310 cm3), water (30 cm3), and 10% Pd on carbon, 50% water content (12.3 g) were hydrogenated at 50 psi and 50°C for 18-24 h in a Parr shaker. The Pd catalyst was filtered off, and the resulting pale yellow filtrate was azeotropically distilled at constant volume to remove water. The resulting solution was treated with triethylamine (46 g, 456 mmol) and heated to reflux. Benzaldehyde (15.0 g, 141 mmol) was added dropwise over 15 min. The reaction mixture was heated at reflux for 4 h to form (1α,5α,6α)-6-benzylidenylamino-3-azabicyclo[3.1.0]hexane in situ. The resulting orange solution was cooled to 40°-50°C, and ethyl 7-chloro-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid (42.45 g, 111 mmol; see United Kingdom Patent Publication No. GB 2,191,776) and triethylamine (13.1 g, 130 mmol) were added. The resulting slurry was heated at reflux for 16-18 h, cooled to 20°C and stirred for 5 h. The slurry was filtered, and the compound was isolated as a white solid (75.5% yield based on (1α,5α,6α)-3-N-benzyl-6-nitro-2,4-dioxo-3- azabicyclo[3.1.0]hexane; 96.6% based on ethyl 7-chloro-1-(2,4- difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid). The ethyl (1α,5α,6α)-7-(6-benzylidenylamino-3-azabicyclo[3.1.0]hex- 3yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3- carboxylate was recrystallized from acetonitrile, melting point 148°-155°C decomp.
  Tetrahydrofuran (250 cm3), ethyl (1α,5α,6α)-7-(6-benzylidenylamino-3- azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo- 1,8-naphthyridine-3-carboxylate (25.05 g, 47 mmol) obtained above, and water (250 cm3) were treated with 97% methanesulfonic acid (13.3 g, 138 mmol) and heated to reflux for 24 h. The resulting solution was cooled to 45°C, treated with activated carbon (2.5 g) for 1 h and filtered. The resulting filtrate was concentrated under vacuum to approximately 25% of its or

• Trademarks

  Trovan (Pfizer).

• Therapeutic Function

  Antibacterial

• Biologische Aktivität

  Fluoroquinolone antibiotic. Inhibits bacterial DNA topoisomerase IV and DNA gyrase and forms a stable quinolone-DNA complex with these enzymes which reversibly inhibits DNA synthesis. Displays potent activity against gram-positive and gram-negative bacteria.

• Biochem/physiol Actions

  Trovafloxacin mesylate acts as a pannexin1 (Panx1) inhibitor.

• Lager

  Desiccate at RT

Trovafloxacin Mesylate Upstream-Materialien And Downstream Produkte

Trovafloxacin Mesylate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(64)Suppliers